Catalyst Financial Partners LLC Buys 78 Shares of Zoetis Inc. (NYSE:ZTS)

Catalyst Financial Partners LLC grew its stake in Zoetis Inc. (NYSE:ZTSFree Report) by 3.6% during the third quarter, Holdings Channel reports. The firm owned 2,247 shares of the company’s stock after purchasing an additional 78 shares during the period. Catalyst Financial Partners LLC’s holdings in Zoetis were worth $439,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of ZTS. Quarry LP increased its position in shares of Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the last quarter. Fortitude Family Office LLC boosted its stake in Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after acquiring an additional 222 shares during the last quarter. LRI Investments LLC bought a new position in shares of Zoetis during the 1st quarter valued at approximately $43,000. Central Valley Advisors LLC purchased a new stake in shares of Zoetis during the 2nd quarter worth approximately $49,000. Finally, Future Financial Wealth Managment LLC bought a new stake in shares of Zoetis in the 3rd quarter worth approximately $59,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Up 0.8 %

Shares of ZTS stock opened at $182.74 on Thursday. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The firm has a fifty day moving average price of $189.02 and a 200-day moving average price of $178.28. The company has a market cap of $82.79 billion, a price-to-earnings ratio of 35.22, a PEG ratio of 2.79 and a beta of 0.89. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92.

Zoetis (NYSE:ZTSGet Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the previous year, the firm posted $1.41 EPS. Zoetis’s revenue for the quarter was up 8.3% compared to the same quarter last year. As a group, equities analysts predict that Zoetis Inc. will post 5.83 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be given a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.95%. Zoetis’s dividend payout ratio (DPR) is 33.14%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ZTS shares. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. BTIG Research upped their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. JPMorgan Chase & Co. lifted their price objective on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Stifel Nicolaus raised their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Finally, Piper Sandler raised their target price on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $221.44.

View Our Latest Stock Analysis on ZTS

Zoetis Company Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Articles

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.